PLx Pharma (NASDAQ:PLXP) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research lowered shares of PLx Pharma (NASDAQ:PLXP) from a hold rating to a sell rating in a report issued on Tuesday morning, Zacks.com reports.

According to Zacks, “PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe and effective aspirin products. PLx Pharma Inc., formerly known as Dipexium Pharmaceuticals Inc., is based in NEW YORK, United States. “

Separately, ValuEngine lowered shares of PLx Pharma from a hold rating to a sell rating in a research report on Thursday, August 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of Hold.

PLXP stock opened at $5.00 on Tuesday. The firm has a market cap of $46.13 million, a PE ratio of -3.70 and a beta of 5.18. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.53 and a current ratio of 3.53. The firm’s 50 day moving average price is $5.65 and its 200-day moving average price is $5.65. PLx Pharma has a one year low of $1.00 and a one year high of $7.41.

PLx Pharma (NASDAQ:PLXP) last released its quarterly earnings results on Friday, August 9th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.05). The firm had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $0.33 million. PLx Pharma had a negative net margin of 2,056.16% and a positive return on equity of 31.27%. Equities research analysts predict that PLx Pharma will post -1.85 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in PLx Pharma by 150.1% in the 2nd quarter. BlackRock Inc. now owns 9,897 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 5,939 shares during the last quarter. Nottingham Advisors Inc. acquired a new stake in PLx Pharma in the 2nd quarter valued at approximately $422,000. Renaissance Technologies LLC increased its holdings in PLx Pharma by 10.4% in the 2nd quarter. Renaissance Technologies LLC now owns 64,711 shares of the biotechnology company’s stock valued at $466,000 after purchasing an additional 6,099 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in PLx Pharma by 29.2% in the 2nd quarter. Vanguard Group Inc. now owns 145,649 shares of the biotechnology company’s stock valued at $1,049,000 after purchasing an additional 32,874 shares during the last quarter. Hedge funds and other institutional investors own 21.14% of the company’s stock.

PLx Pharma Company Profile

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

Recommended Story: Benefits of owning preferred stock

Get a free copy of the Zacks research report on PLx Pharma (PLXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.